Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
PLOS Pathogens · 2023
DOI: 10.1371/journal.ppat.1011772 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Thandeka Moyo-Gwete und 24 weiteren Autor:innen. Beteiligte Einrichtung: SA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Ad26COVS1, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIAID NIH HHS, South African Medical Research Council.
Abstract (Originalsprache)
The impact of previous SARS-CoV-2 infection on the durability of Ad26.COV2.S vaccine-elicited responses, and the effect of homologous boosting has not been well explored. We followed a cohort of healthcare workers for 6 months after receiving the Ad26.COV2.S vaccine and a further one month after they received an Ad26.COV2.S booster dose. We assessed longitudinal spike-specific antibody and T cell responses in individuals who had never had SARS-CoV-2 infection, compared to those who were infected with either the D614G or Beta variants prior to vaccination. Antibody and T cell responses elicited by the primary dose were durable against several variants of concern over the 6 month follow-up period, regardless of infection history. However, at 6 months after first vaccination, antibody binding, neutralization and ADCC were as much as 59-fold higher in individuals with hybrid immunity compared to those with no prior infection. Antibody cross-reactivity profiles of the previously infected groups were similar at 6 months, unlike at earlier time points, suggesting that the effect of immune imprinting diminishes by 6 months. Importantly, an Ad26.COV2.S booster dose increased the magnitude of the antibody response in individuals with no prior infection to similar levels as those with previous infection. The magnitude of spike T cell responses and proportion of T cell responders remained stable after homologous boosting, concomitant with a significant increase in long-lived early differentiated CD4 memory T cells. Thus, these data highlight that multiple antigen exposures, whether through infection and vaccination or vaccination alone, result in similar boosts after Ad26.COV2.S vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- SA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
- Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa.
- Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
- Division of Medical Virology, Department of Pathology; University of Cape Town; Observatory, South Africa.
- Department of Medicine, University of Cape Town and Groote Schuur Hospital; Observatory, South Africa.
- Cape Heart Institute, Faculty of Health Sciences, University of Cape Town; Observatory, South Africa.
ORCID-Profile: Penny L Moore
Förderung
- Wellcome Trust
- NIAID NIH HHS
- South African Medical Research Council
- Department of Science and Innovation, South Africa
- National Research Foundation South Africa
- Centre for the AIDS Programme of Research in South Africa
- Bill and Melinda Gates Foundation
- Poliomyelitis Research Foundation
Zitieren
APA
Moyo-Gwete, T., Richardson, S. I., Keeton, R., Hermanus, T., Spencer, H., Manamela, N. P., Ayres, F., Makhado, Z., Motlou, T., Tincho, M. B., Benede, N., Ngomti, A., Baguma, R., Chauke, M. V., Mennen, M., Adriaanse, M., Skelem, S., Goga, A., Garrett, N., …, & Moore, P. L. (2023). Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011772
Vancouver
Moyo-Gwete T, Richardson SI, Keeton R, Hermanus T, Spencer H, Manamela NP, et al. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011772
BibTeX
@article{MoyoGwete2023,
author = {Moyo-Gwete, Thandeka and Richardson, Simone I and Keeton, Roanne and Hermanus, Tandile and Spencer, Holly and Manamela, Nelia P and Ayres, Frances and Makhado, Zanele and Motlou, Thopisang and Tincho, Marius B and Benede, Ntombi and Ngomti, Amkele and Baguma, Richard and Chauke, Masego V and Mennen, Mathilda and Adriaanse, Marguerite and Skelem, Sango and Goga, Ameena and Garrett, Nigel and Bekker, Linda-Gail and Gray, Glenda and Ntusi, Ntobeko A B and Riou, Catherine and Burgers, Wendy A and Moore, Penny L},
title = {Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection},
journal = {PLOS Pathogens},
year = {2023},
doi = {10.1371/journal.ppat.1011772}
}
EUVIMED